Askal A Ali

Perry Paige Bldg Room #119

Mondays •  2:00 p.m - 3:OO p.m
Wednesdays • 2:00 p.m - 3:OO p.m

Advanced Studying •  Mon. Wed. Fri — 9:15am-10:30am
Advanced Studying •  Mon. Wed. Fri — 1:15pm-2:30pm
Appreciation of Studying •  Tu. Th.— 9:15am-10:30am
Colloquium in Studying •  Tu. Th — 1:15pm-2:30pm

---

---

Dr. Askal Ayalew Ali received her Ph.D in Pharmacoeconomics from Florida Agriculture and Mechanical University, College of Pharmacy and Pharmaceutical Sciences (COPPS). Immediately following graduation, she was offered and accepted an assistant professorship. Her decision was heavily influenced by her strong commitment to the Pharm D and graduate education programs within COPPS.  She has published several peer reviewed papers and has been awarded the FAMU COPPS 2017 teacher of the Year Award. Currently, Dr. Ali is mentoring 4 students and serving as dissertation committee member in ESAP and Institute of Public Health students. In 2019 she received a Mini Medical Marijuana Research and Educational grant from FAMU. The aim of this min grant is to measure the knowledge and perceptions of pediatric cancer patient care giver’s regarding medical marijuana. In addition, she is a co-investigator on a 2019 awarded U54-RCMI NIH grant project 3 entitled: Test Up Now Education Program (TUNE-UP). Her role in the TUNE-UP grant is to examine the cost-effectiveness of a community health advisors educational intervention to improve colorectal cancer screening rate among African Americans.

---

---

• Pharmacoeconomics/Health Economics
• Decision Modeling, patient satisfaction and self-rated health status
• Comparative Effectiveness research
• Patient-centered outcomes research
• Health Disparities
• Data Collection and Evidence synthesis (systemic reviews and meta-analyses)

---

---

• Pharmacoeconomics and Health Outcomes Research, Ph.D. • 2016
  Florida A&M University
• Eastern Illinois University • 2010
  M.S. in Economics
• Bahir Dar University (Ethiopia) • 2005
  B.S. in Economics

---

---

• Diaby, V., Ali, A. A., & Montero, A. J. (2019). Value assessment frameworks in the United States: a call for patient engagement.
• Ali, A. A., Tawk, R., Xiao, H., Campbell, E., Semykina, A., Montero, A. J., ... & Diaby, V. (2019). Comparative effectiveness of radiotherapy for early‐stage hormone receptor‐positive breast cancer in elderly women using real‐world data. Cancer medicine, 8(1), 117-127.
• Ali, A. A., Xiao, H., Tawk, R., Campbell, E., Semykina, A., Montero, A. J., & Diaby, V. (2017). Comparison of health utility weights among elderly patients receiving breast-conserving surgery plus hormonal therapy with or without radiotherapy. Current medical research and opinion, 33(2), 391-400.
• Diaby, V., Ali, A. A., Williams, K. J., Ezendu, K., Soto-Perez-de-Celis, E., Chavarri-Guerra, Y., & de Lima Lopes, G. (2017). Economic evaluation of sequencing strategies in HER2-positive metastatic breast cancer in Mexico: a contrast between public and private payer perspectives. Breast cancer research and treatment, 166(3), 951-963.
• Tan, F., Xiao, H., Gummadi, S., Koniaris, L. G., Feldman, J. D., Ali, A., ... & Huang, Y. (2017). Impact of body mass index on prognosis for breast cancer patients.
• Diaby, V., Adunlin, G., Ali, A. A., Zeichner, S. B., de Lima Lopes, G., Kohn, C. G., & Montero, A. J. (2016). Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States. Breast cancer research and treatment, 160(1), 187-196.
• Diaby, V., Ali, A. A., Adunlin, G., Kohn, C. G., & Montero, A. J. (2016). Parameterization of a disease progression simulation model for sequentially treated metastatic human epidermal growth factor receptor 2 positive breast cancer patients. Current medical research and opinion, 32(6), 991-996.
• Ali, A. A., Xiao, H., Campbell, E. S., & Diaby, V. (2015). Improving health care decision making in the USA through comparative effectiveness research: the role of economic evaluation. Pharmaceutical Medicine, 29(5), 247-253.
• Diaby, V., Adunlin, G., Ali, A. A., & Tawk, R. (2014). Using quality-adjusted progression-free survival as an outcome measure to assess the benefits of cancer drugs in randomized-controlled trials: case of the BOLERO-2 trial. Breast cancer research and treatment, 146(3), 669-673.
• Diaby, V., Adunlin, G., Zeichner, S. B., Avancha, K., Lopes, G., Gluck, S., & Montero, A. J. (2014). Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer. Breast cancer research and treatment, 147(2), 433-441.